JP2008510770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510770A5 JP2008510770A5 JP2007528833A JP2007528833A JP2008510770A5 JP 2008510770 A5 JP2008510770 A5 JP 2008510770A5 JP 2007528833 A JP2007528833 A JP 2007528833A JP 2007528833 A JP2007528833 A JP 2007528833A JP 2008510770 A5 JP2008510770 A5 JP 2008510770A5
- Authority
- JP
- Japan
- Prior art keywords
- halogen
- sor
- aryl
- heterocyclyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000002577 pseudohalo group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims 2
- 201000010927 Mucositis Diseases 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229910052731 fluorine Chemical group 0.000 claims 2
- 239000011737 fluorine Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04020291 | 2004-08-26 | ||
| PCT/EP2005/054096 WO2006021547A1 (de) | 2004-08-26 | 2005-08-19 | Pteridinone als plk (polo like kinase) inhibitoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510770A JP2008510770A (ja) | 2008-04-10 |
| JP2008510770A5 true JP2008510770A5 (enExample) | 2008-10-09 |
Family
ID=34926314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528833A Pending JP2008510770A (ja) | 2004-08-26 | 2005-08-19 | Ｐｌｋ阻害剤としての新規プテリジノン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060047118A1 (enExample) |
| EP (1) | EP1786817A1 (enExample) |
| JP (1) | JP2008510770A (enExample) |
| CA (1) | CA2575804A1 (enExample) |
| WO (1) | WO2006021547A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US20080096905A1 (en) * | 2005-03-25 | 2008-04-24 | Glaxo Group Limited | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives |
| NZ594628A (en) * | 2005-10-07 | 2013-04-26 | Exelixis Inc | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka |
| CN102746298A (zh) | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| WO2008032162A1 (en) | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| BRPI0719883A2 (pt) * | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
| EP2079743B1 (en) * | 2006-10-25 | 2012-01-25 | Chroma Therapeutics Limited | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
| GB0621203D0 (en) * | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| CA2709202C (en) | 2007-12-19 | 2013-04-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| KR101754664B1 (ko) * | 2009-12-18 | 2017-07-06 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도 |
| WO2011101369A1 (en) * | 2010-02-17 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| KR20160035613A (ko) | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| EP2776444A4 (en) | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
| DE112013002484B4 (de) * | 2012-05-14 | 2023-05-04 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | Pteridinketon-Derivat und Anwendungen desselben als EGFR-, BLK- und FLT3-Inhibitor |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| CN105294681B (zh) | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| JP6778259B2 (ja) * | 2015-10-01 | 2020-10-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体 |
| CN106892922B (zh) * | 2015-12-18 | 2019-04-19 | 华东理工大学 | 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用 |
| CN108721298A (zh) * | 2017-04-19 | 2018-11-02 | 华东理工大学 | 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用 |
| EP3833353A4 (en) * | 2018-08-10 | 2022-08-24 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| AU2020260018A1 (en) * | 2019-04-19 | 2021-11-04 | Pfizer Inc. | Anti-proliferative agents for treating PAH |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN113801118A (zh) * | 2020-06-12 | 2021-12-17 | 华东理工大学 | 作为rsk抑制剂的蝶啶酮衍生物及其应用 |
| JP7756374B2 (ja) * | 2021-03-08 | 2025-10-20 | 曁南大学 | ピリドピリミジン系化合物及びその使用 |
| CN113087708A (zh) * | 2021-04-06 | 2021-07-09 | 南方医科大学 | 一种蝶啶酮类化合物及其应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| WO2001019825A1 (en) * | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| KR20020070520A (ko) * | 2000-01-27 | 2002-09-09 | 워너-램버트 캄파니 | 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체 |
| KR20020075805A (ko) * | 2000-03-06 | 2002-10-05 | 워너-램버트 캄파니 | 5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제 |
-
2005
- 2005-08-19 WO PCT/EP2005/054096 patent/WO2006021547A1/de not_active Ceased
- 2005-08-19 CA CA002575804A patent/CA2575804A1/en not_active Abandoned
- 2005-08-19 EP EP05784644A patent/EP1786817A1/de not_active Withdrawn
- 2005-08-19 JP JP2007528833A patent/JP2008510770A/ja active Pending
- 2005-08-24 US US11/211,048 patent/US20060047118A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510770A5 (enExample) | ||
| CN114728974A (zh) | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 | |
| JP2008506644A5 (enExample) | ||
| CN115335372A (zh) | 八氢吡嗪并二氮杂萘啶二酮类化生物 | |
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| JP2010511721A5 (enExample) | ||
| CN113939514A (zh) | 吡咯并嘧啶类化合物及其应用 | |
| JP2009504764A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2013540755A5 (enExample) | ||
| CN113993860A (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
| JP2010540556A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| JP2008510691A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2008533191A5 (enExample) | ||
| CN112368281A (zh) | 作为pde3/pde4双重抑制剂的三并环类化合物 | |
| JP2016531126A5 (enExample) | ||
| CN111683928A (zh) | 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物 | |
| JP2020502047A5 (enExample) | ||
| JP2009536221A5 (enExample) | ||
| CN114761411A (zh) | 作为erk抑制剂的螺环类化合物及其应用 |